Claims for Patent: 7,635,468

Summary for Patent: 7,635,468

Title:	Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine
Abstract:	Vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such vaccine, furthermore transfected human tumor cells for their use as a vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. .sctn.1.72(b). As stated in 37 C.F.R. .sctn.1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading \"Abstract of the Disclosure.\" The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.
Inventor(s):	Dobric; Tomislav (Berlin, DE), Wittig; Burghardt (Berlin, DE), Schmidt; Manuel (Berlin, DE)
Assignee:	Mologen AG (Berlin, DE)
Application Number:	11/482,233
Patent Claims:	1. A human tumor cell transfected ex-vivo with nucleic acid molecules encoding: a) interleukin-7 (IL-7), granulocyte-macrophage colony stimulating factor (GM-CSF), CD40L/CD154 and B7.1/CD80, or b) interleukin-7 (IL-7), granulocyte-macrophage colony stimulating factor (GM-CSF), and CD40L/CD154 and comprising the corresponding expression constructs, wherein the expression construct is: a) a plasmid; or b) a linear double stranded, covalently closed expression cassette comprising essentially solely a CMV promoter, an intron the encoding gene sequence and a poly adenylation sequence being closed on both ends of the double strand by a short loop of single strands nucleotide residues, wherein said tumor cell is an allogeneic tumor cell of a renal cell carcinoma cell line deposited under accession number DSM ACC 2635 at the DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH. 2. A vaccine for the treatment of patients who suffer from tumor diseases, said vaccine containing tumor cells of a genetically not identical (different) donor of the same species (allogeneic), where the tumor cells were transfected previously ex-vivo with nucleic acid molecules encoding one of: a) interleukin-7 (IL-7), granulocyte-macrophage colony stimulating factor (GM-CSF), CD40IL/CD154 and B7.1/CD80; or b) interleukin-7 (IL-7), granulocyte-macrophage colony stimulating factor (GM-CSF) and CD40L/CD154, wherein the encoding nucleic acid constructs are present in one or more expression constructs, wherein the one expression construct is a linear double stranded, covalently closed expression cassette comprising essentially solely a CMV promoter, an intron, the encoding sequence and a polyadenylation sequence being closed on both ends of the double strand by a short loop of single stranded nucleotide residues, wherein said vaccine comprises additional immune modulating oligonucleotides as an adjuvant; and the immune modulating oligonucleotide: e) comprises a sequence of the base sequence N.sup.1N.sup.2CGN.sup.3N.sup.4, where N.sup.1N.sup.2 is an element selected from the group comprising GT, GG, GA, AT or AA, N.sup.3N.sup.4 is an element selected from the group comprising CT or TT, and C is deoxycytosine and T is desoxyguanosine, A is desoxycytosine and G is desoxythymidine, and f) comprises a circular strand deoxyribonucleic acid with a partially complementary antiparallel base sequence and is of dumbbell shaped form, wherein the sequence with the base sequence N.sup.1N.sup.2CGN.sup.3N.sup.4, is positioned in a single stranded region of the oligodeoxyribonucleotide and comprises 40 to 200 nucleotides; and said vaccine comprises a pharmaceutically acceptable carrier and the tumor cells are derived from the renal cell carcinoma deposited under accession number DSM ACC2635 at the DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH. 3. A method of making a vaccine for the treatment of patients who suffer from tumor diseases, where tumor cells of a genetically not identical (different) donor of the same species (allogeneic) are transfected ex-vivo with nucleic acid molecules encoding: a) interleukin-7, granulocytes-macrophage colony stimulating factor (GM-CSF), CD40L/CD154 and B7.1/CD80, or b interleukin-7 (IL-7), granulocyte-macrophage colony stimulating factor (GM-CSF), and CD4-L/CD154 and subsequently are transferred into an applicable pharmaceutical composition, wherein the tumor cells of the renal carcinoma cell line deposited under accession number DSM ACC 2635 at the DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH are employed. 4. The method according to claim 3, wherein the transfection method being ballistic transfer, polycation transfection, calcium phosphate precipitation, microinjection, protoplast fusion, liposome fusion, viral transfection, lipofection and/or electroporation.

Details for Patent 7,635,468

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2023-12-30
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2023-12-30
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2023-12-30